{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:13:35Z","timestamp":1761959615912,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":247,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.lrr.2022.100348","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T05:02:00Z","timestamp":1662440520000},"page":"100348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anti-inflammatory effects of ruxolitinib on chronic neutrophilic leukemia harboring CSF3R-T618I mutation with bilateral renal abscesses"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-4802","authenticated-orcid":false,"given":"Naohi","family":"Sahara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Yusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eigo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiya","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arinobu","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2022.100348_bib0001","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lrr.2022.100348_bib0002","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ajh.25688","article-title":"Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management","volume":"95","author":"Szuber","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lrr.2022.100348_bib0003","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00277-016-2664-4","article-title":"Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia","volume":"95","author":"Stahl","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.lrr.2022.100348_bib0004","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.19.00895","article-title":"Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia","volume":"38","author":"Dao","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lrr.2022.100348_bib0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00277-020-04152-w","article-title":"Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation","volume":"100","author":"Hinze","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.lrr.2022.100348_bib0006","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lrr.2022.100348_bib0007","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lrr.2022.100348_bib0008","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/bjh.14456","article-title":"CSF3R T618I, ASXL1 G942 fs and STAT5B N642H trimutation co-contribute to a rare chronic neutrophilic leukaemia manifested by rapidly progressive leucocytosis, severe infections, persistent fever and deep venous thrombosis","volume":"180","author":"Luo","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lrr.2022.100348_bib0009","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lrr.2022.100348_bib0010","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3109\/10428194.2015.1004670","article-title":"Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis","volume":"56","author":"Mascarenhas","year":"2015","journal-title":"Leuk. Lymphoma."},{"key":"10.1016\/j.lrr.2022.100348_bib0011","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.2830410110","article-title":"Elevated neutrophil function in chronic neutrophilic leukemia","volume":"41","author":"Ohtsuki","year":"1992","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lrr.2022.100348_bib0012","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000206273","article-title":"Cellular abnormalities and reduced colony-forming cells in chronic neutrophilic leukaemia","volume":"73","author":"Mehrotra","year":"1985","journal-title":"Acta Haematol"},{"key":"10.1016\/j.lrr.2022.100348_bib0013","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ajh.2830120208","article-title":"Functional characterization of the cells in chronic neutrophilic leukemia","volume":"12","author":"Dotten","year":"1982","journal-title":"Am. J. Hematol."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:09:25Z","timestamp":1761959365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048922000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":13,"alternative-id":["S2213048922000607"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100348","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-inflammatory effects of ruxolitinib on chronic neutrophilic leukemia harboring CSF3R-T618I mutation with bilateral renal abscesses","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100348"}}